Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Travesol is a 10% amino acid solution primarily utilized as a component of parenteral nutrition to provide a source of nitrogen and essential amino acids for patients who cannot receive adequate oral or enteral intake. In the context of clinical research, specifically at Penn State Health Milton S. Hershey Medical Center, it is being evaluated for its potential to prevent acute kidney injury (AKI) in patients undergoing elective cardiac surgery with cardiopulmonary bypass. The proposed mechanism for this protective effect involves the induction of renal vasodilation and an increase in the glomerular filtration rate (GFR), which enhances the kidney's resilience to ischemic stress during surgery. It is administered via intravenous infusion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Travesol.